Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Polar Power, Inc. is providing an update on its efforts to regain compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million. The company has until October 28, 2026, to demonstrate compliance and has executed several financings, including convertible notes and Series A Preferred Stock issuances, to bolster its equity position. These transactions, along with an equity line of credit with Roth Principal Investments, are intended to meet the Nasdaq Capital Market's continued listing standards.
High Roller Technologies has commercially launched ROLR™, its real-money prediction markets platform, for eligible U.S. customers following a successful beta period. The platform offers event-based contracts through a partnership with Crypto.com | Derivatives North America (CDNA) and is expected to begin generating revenue in Q4 2026.
Counterparty
Crypto.com | Derivatives North America
“Today’s full commercial launch of our prediction markets platform is a defining milestone for High Roller as we bring ROLR to the public and begin the next phase of our growth.”
Seth Young, Chief Executive Officer of High Roller Technologies
“Our goal is to make prediction markets accessible and engaging through an intuitive customer experience, and our experience operating real-money consumer platforms provides a strong foundation for building this business.”
Seth Young, Chief Executive Officer of High Roller Technologies
Amneal Pharmaceuticals M&A Deal with Kashiv BioSciences, LLC
Amneal Pharmaceuticals filed an amendment to its previous 8-K to provide required historical financial statements and pro forma financial information following its completed acquisition of Kashiv BioSciences, LLC. The acquisition was originally completed on August 10, 2026, pursuant to a Membership Interest Purchase Agreement dated April 21, 2026.
Red Cat Holdings, through its subsidiary SMOT Acquisition GmbH, has launched a voluntary public cash tender offer to acquire all outstanding shares of Austrian engine manufacturer Steyr Motors AG for EUR 39.00 per share. The transaction is intended to strengthen Red Cat's 'Blue Ops' uncrewed surface vessel (USV) strategy by integrating Steyr's marine engine technology and European manufacturing base.
Counterparty
Steyr Motors AG
“This proposed transaction is about investing in that foundation and helping Steyr Motors grow. We see Austria as central to the future of the business, and our goal is to provide additional resources, customer access and long-term demand that can support Steyr Motors’ employees, operations and continued expansion.”
Jeff Thompson, Chief Executive Officer of Red Cat
“Four years into Steyr Motors’ transformation, I am very excited to lead its next chapter with Red Cat as strategic partner on our side. Our engineering and Red Cat’s reach into international markets are the basis for joint growth, and Red Cat stands firmly behind our site and our people.”
Reliance Global Group M&A Deal with Steyr Motors AG
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG for EUR 39.00 per share in cash. The deal is intended to strengthen Red Cat's autonomous maritime portfolio by integrating Steyr's marine engine technology and European manufacturing base.
Nathans Famous M&A Deal with Smithfield Foods, Inc.
Stockholders of Nathan’s Famous, Inc. approved the previously announced merger agreement with Smithfield Foods, Inc. at a special meeting held on October 23, 2026. Under the agreement, Nathan’s will become a wholly-owned subsidiary of Smithfield Foods following the completion of the merger.
Valor Energy Inc entered into a securities purchase agreement to sell 2,145,923 shares of common stock in a private placement. The offering is expected to generate gross proceeds of approximately $5.0 million. The company intends to use the net proceeds for AI data center project development and general corporate purposes.
Blue Owl Credit Income Corp. sold 464,303 unregistered shares of Class I common stock for approximately $4.26 million in a private offering to feeder vehicles. The company also reported that its continuous public offering has raised over $22.49 billion in total consideration to date across all share classes.
1 800 Flowers Com Divestiture to PlanetArt, LLC for $45M
1-800-FLOWERS.COM completed the sale of its Personalization Businesses, including Personalization Mall, Things Remembered, and Personalization Universe, to PlanetArt, LLC for $45.0 million in cash. The company used a portion of the net proceeds to prepay outstanding term loans under its existing credit facility.
Blackstone Private Real Estate Credit & Income Fund Capital Raise of $2.73M
Blackstone Private Real Estate Credit and Income Fund sold 104,054 unregistered common shares of beneficial interest to investors in a private placement. The transaction, finalized on October 21, 2026, raised approximately $2.73 million in gross proceeds. The offering was conducted under exemptions from registration provided by Section 4(a)(2) and Regulation D/S of the Securities Act.
EQT Infrastructure Company LLC sold 3,147,858 unregistered shares to third-party investors for aggregate cash consideration of approximately $92.1 million. The shares were sold at a price equal to the transactional net asset value per share as part of the company's continuous private offering, which has raised over $1.1 billion since inception in February 2026.
EQT Private Equity Company LLC sold 663,060 unregistered shares to third-party investors for aggregate cash consideration of approximately $19.1 million. The shares were sold across multiple classes (Class I, J1, J2, and S) at prices based on the company's Transactional Net Asset Value per share. Since its inception in July 2025, the company has raised approximately $880.2 million through its continuous private offering.
Zevia PBC entered into a securities purchase agreement with Bubble Holdings, LLC (an affiliate of GP Investments, Ltd.) to raise up to $20 million through the issuance of Series A Senior Convertible Preferred Stock. The company completed an initial closing of $15 million on October 22, 2026, with a deferred closing of $5 million contingent on meeting specific 2026 net sales and Adjusted EBITDA targets.
Value
$15M
Counterparty
Bubble Holdings, LLC
“This growth equity investment marks an important milestone in Zevia’s evolution and provides the capital, strategic resources, and operational expertise to accelerate our medium- and long-term growth agenda.”
“We are thrilled to partner with Zevia and help support accelerated profitable growth. The team’s execution strengths and clear growth plan give us confidence in Zevia’s potential to become a leading everyday alternative to traditional soda, as consumers increasingly seek healthier options without artificial sweeteners.”
Ionis Pharmaceuticals and its partner Roche announced positive Phase 3 IMAgINATION study results for sefaxersen in patients with IgA nephropathy. The trial met its primary endpoint, demonstrating a statistically significant 43.1% reduction in proteinuria compared to placebo at 37 weeks, with a safety profile consistent with earlier studies.
Counterparty
Roche
“These data support our belief that sefaxersen is uniquely positioned to treat IgA nephropathy, demonstrating significant and clinically meaningful reduction in proteinuria and offering the potential to help reduce the need for long-term dialysis or kidney transplantation.”
Brett P. Monia, Ph.D., chief executive officer, Ionis
“Sefaxersen is a powerful example of the broad impact of Ionis' innovative science, and based on these positive data, we believe it has the potential to be an important new treatment option for people living with IgA nephropathy.”
Brett P. Monia, Ph.D., chief executive officer, Ionis
Lord Abbett Private Credit Fund Capital Raise of $34.1M
Lord Abbett Private Credit Fund issued and sold approximately 1.37 million common shares for aggregate proceeds of $34.1 million. The private placement was conducted at a price of $24.86 per share and was exempt from registration under Section 4(a)(2) and Regulation D. The fund also provided a portfolio update showing $2.36 billion in total loan commitments across 70 portfolio companies.
T3 Defense Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $10 million. The company resolved a previous deficiency caused by the non-cash liability classification of warrants, which had temporarily driven stockholders' equity into a deficit. Following the exercise of 96% of those warrants, the company reported pro forma stockholders' equity of approximately $99.9 million as of September 30, 2026.
Worthington Steel provided a status update on its acquisition of Kloeckner & Co SE, noting that a proposed domination and profit and loss transfer agreement (DPLTA) failed to receive required shareholder approval. Despite the vote, Worthington Steel remains the majority owner with a 62% stake and will continue to consolidate Kloeckner's financial results while pursuing synergies under the existing governance structure.
Vista Credit Strategic Lending Capital Raise of $7.23M
Vista Credit Strategic Lending Corp. sold 371,804.601 shares of its Class I common stock for total consideration of approximately $7.23 million. The unregistered sale was conducted via subscription agreements with accredited investors and non-U.S. persons. The company also reported a preliminary net asset value (NAV) per share of $19.44 as of September 30, 2026.
BancFirst Corporation completed the acquisition of Spirit BankCorp, Inc. and its subsidiary SpiritBank, a privately held community bank headquartered in Tulsa, Oklahoma. SpiritBank, which has approximately $866.8 million in total assets and $776.4 million in deposits, was merged into BancFirst upon the closing of the transaction.
AB Private Credit Investors Capital Raise of $16.7M
AB Private Credit Investors Corp delivered a capital call notice to its investors for an aggregate offering price of approximately $16.69 million. The sale of common stock is being conducted under existing subscription agreements where investors fund capital commitments on an as-needed basis, with the closing expected around November 2, 2026.
Perspective Therapeutics announced updated interim Phase 1/2a results for [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, showing objective response rates of 33% and 50% in Cohorts 2 and 3, respectively. The data demonstrated a 72% progression-free survival rate at 18 months with no dose-limiting toxicities, supporting the company's plan to initiate Phase 3 trials in 2027.
Bolt Biotherapeutics M&A Deal with Prana Therapies, Inc.
Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger, issuing common and Series D preferred stock to Prana shareholders. Following the merger and a concurrent $120 million private placement, former Prana equityholders will own approximately 51.7% of the combined company. The transaction shifts Bolt's focus to Prana's INSPIRE platform and its lead bispecific antibody candidate, PRA-216, for inflammatory diseases.
ExchangeRight Income Fund sold 16,740 Class D Common Shares for gross proceeds of $462,000 between October 8 and October 21, 2026. The sale is part of an ongoing continuous private placement offering of up to $2.165 billion in common shares.
Eikon Therapeutics presented initial and updated Phase 1/2 clinical data for its PARP1-selective inhibitors (EIK1003, EIK1004) and WRN helicase inhibitor (EIK1005) at the 2026 ESMO Congress. EIK1003 monotherapy showed a 31.3% objective response rate in PARP-naïve patients with HRR-mutated tumors, while EIK1004 and EIK1005 demonstrated favorable safety and tolerability profiles in early dose-escalation cohorts.
“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs. The EIK1003 results support continued development both as monotherapy and in combination with established cancer treatments, while the initial EIK1004 findings support further evaluation of our CNS-penetrant PARP1 inhibitor. The first clinical results for EIK1005, our internally derived WRN helicase inhibitor, mark an important step in translating Eikon’s discovery science into potential new medicines for patients.”
Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon
Arcosa, Inc. completed its merger with CRH Americas, Inc., a subsidiary of CRH plc, resulting in Arcosa becoming a wholly owned subsidiary of CRH. Under the terms of the agreement, Arcosa stockholders received $150.00 in cash for each share of common stock held. In connection with the closing, Arcosa terminated its $1.4 billion senior secured credit facility and repaid approximately $450.1 million in outstanding obligations.
Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M
Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.
Crh Public Ltd Signs $8.5B M&A Deal with Arcosa, Inc.
CRH completed its acquisition of Arcosa, Inc., a leading U.S. provider of aggregates and critical infrastructure products, for an enterprise value of approximately $8.5 billion. The deal reinforces CRH's position as the top infrastructure player in North America and increases its exposure to major road, water, energy, and data projects.
Value
$8.5B
Counterparty
Arcosa, Inc.
“Arcosa is an excellent strategic fit for CRH and fully aligns with our growth ambitions. With high-quality aggregates assets and attractive positions in the growing U.S. energy transmission market, the acquisition strengthens our connected portfolio and reinforces our position as the #1 infrastructure player in North America. We look forward to welcoming our Arcosa colleagues into CRH and executing on the strong growth opportunities ahead.”
Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO and open-label extension trials for ARD-101 in Prader-Willi syndrome. The data showed reductions in hunger scores (HQ-CT) during treatment that returned to baseline upon discontinuation, and the FDA has lifted a full clinical hold on the program. The company plans to meet with the FDA to align on a new Phase 3 trial design using a lower dose, with clinical activities expected to resume in 2027.
Nordson Signs $168M M&A Deal with Contrinex Holding SA
Nordson Corporation, through its subsidiary Nordson London Limited, completed the acquisition of Switzerland-based Contrinex Holding SA for an enterprise value of approximately $168 million. Contrinex is a global leader in high-performance sensors for factory automation, generating approximately $50 million in annual revenue, and will be integrated into Nordson’s Advanced Technology Solutions segment.
TPG Private Equity Opportunities Capital Raise of $73.1M
TPG Private Equity Opportunities, L.P. raised $73.1 million in aggregate consideration through the sale of unregistered limited partnership units on October 1, 2026. The sale was part of the Fund's continuous private offering and included Class I, Class S, and Class F units. The broader T-POP Fund Complex issued interests totaling approximately $103.2 million during the same period.